251 related articles for article (PubMed ID: 24758297)
1. Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover.
Adomas AB; Grimm SA; Malone C; Takaku M; Sims JK; Wade PA
BMC Cancer; 2014 Apr; 14():278. PubMed ID: 24758297
[TBL] [Abstract][Full Text] [Related]
2. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
[TBL] [Abstract][Full Text] [Related]
3. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
4. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.
Kong SL; Li G; Loh SL; Sung WK; Liu ET
Mol Syst Biol; 2011 Aug; 7():526. PubMed ID: 21878914
[TBL] [Abstract][Full Text] [Related]
5. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility.
Theodorou V; Stark R; Menon S; Carroll JS
Genome Res; 2013 Jan; 23(1):12-22. PubMed ID: 23172872
[TBL] [Abstract][Full Text] [Related]
6. NR2F2 Orphan Nuclear Receptor is Involved in Estrogen Receptor Alpha-Mediated Transcriptional Regulation in Luminal A Breast Cancer Cells.
Erdős E; Bálint BL
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168782
[TBL] [Abstract][Full Text] [Related]
7. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.
Lee JY; Park YJ; Oh N; Kwack KB; Park KS
Oncotarget; 2017 Jun; 8(26):42752-42760. PubMed ID: 28514748
[TBL] [Abstract][Full Text] [Related]
8. Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression.
Chen D; Parker TM; Bhat-Nakshatri P; Chu X; Liu Y; Wang Y; Nakshatri H
Oncogene; 2021 Feb; 40(7):1332-1346. PubMed ID: 33420376
[TBL] [Abstract][Full Text] [Related]
9. Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.
Frietze S; O'Geen H; Littlepage LE; Simion C; Sweeney CA; Farnham PJ; Krig SR
BMC Genomics; 2014 Jun; 15(1):520. PubMed ID: 24962896
[TBL] [Abstract][Full Text] [Related]
10. Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data.
Gu F; Hsu HK; Hsu PY; Wu J; Ma Y; Parvin J; Huang TH; Jin VX
BMC Syst Biol; 2010 Dec; 4():170. PubMed ID: 21167036
[TBL] [Abstract][Full Text] [Related]
11. GATA3 mutations found in breast cancers may be associated with aberrant nuclear localization, reduced transactivation and cell invasiveness.
Gaynor KU; Grigorieva IV; Allen MD; Esapa CT; Head RA; Gopinath P; Christie PT; Nesbit MA; Jones JL; Thakker RV
Horm Cancer; 2013 Jun; 4(3):123-39. PubMed ID: 23435732
[TBL] [Abstract][Full Text] [Related]
12. The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancer.
Martin EM; Orlando KA; Yokobori K; Wade PA
Curr Opin Struct Biol; 2021 Dec; 71():65-70. PubMed ID: 34225008
[TBL] [Abstract][Full Text] [Related]
13. GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells.
Abba MC; Nunez MI; Colussi AG; Croce MV; Segal-Eiras A; Aldaz CM
Breast Cancer Res; 2006; 8(6):R64. PubMed ID: 17078870
[TBL] [Abstract][Full Text] [Related]
14. GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice.
Cornelissen LM; de Bruijn R; Henneman L; Kim Y; Zwart W; Jonkers J
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):271-284. PubMed ID: 31218575
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
McCune K; Bhat-Nakshatri P; Thorat MA; Nephew KP; Badve S; Nakshatri H
Cancer Res; 2010 Jan; 70(2):685-96. PubMed ID: 20068169
[TBL] [Abstract][Full Text] [Related]
16. Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
Teinturier R; Abou Ziki R; Kassem L; Luo Y; Malbeteau L; Gherardi S; Corbo L; Bertolino P; Bachelot T; Treilleux I; Zhang CX; Le Romancer M
Breast Cancer Res Treat; 2021 Dec; 190(3):389-401. PubMed ID: 34561764
[TBL] [Abstract][Full Text] [Related]
17. Nutraceuticals known to promote hair growth do not interfere with the inhibitory action of tamoxifen in MCF7, T47D and BT483 breast cancer cell lines.
Baker R; Dell'Acqua G; Richards A; Thornton MJ
PLoS One; 2024; 19(2):e0297080. PubMed ID: 38408073
[TBL] [Abstract][Full Text] [Related]
18. Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.
Cornelissen LM; Henneman L; Drenth AP; Schut E; de Bruijn R; Klarenbeek S; Zwart W; Jonkers J
J Mammary Gland Biol Neoplasia; 2019 Dec; 24(4):305-321. PubMed ID: 31729597
[TBL] [Abstract][Full Text] [Related]
19. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
[TBL] [Abstract][Full Text] [Related]
20. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
